tailieunhanh - Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: Results of a large registry-based cohort analysis

Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
5    164    1    28-11-2024
9    168    0    28-11-2024